Interactive Features

Quiz

Belzutifan vs Everolimus for Quality of Life of Patients With Advanced Clear Cell Renal Cell Carcinoma

03/21/2024

Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?

Did belzutifan improve the time...

03/21/2024

Oncology

Quiz

Quiz: Post-Surgery Everolimus for High-Risk Renal Cell Carcinoma

09/02/2022

In the phase 3 EVEREST trial which looked at everolimus after surgery in patients with high-risk renal cancer, which patients saw the greatest benefit in recurrence-free survival with everolimus?

In the phase 3 EVEREST trial...

09/02/2022

Oncology

Test Your Knowledge

Quiz: Which Study Yields Notable Benefit in Kidney Cancer?

04/15/2021

Which study reported OS results in favor of axitinib plus pembrolizumab, ultimately obtaining the lowest hazard ratio observed for survival in any phase 3 trial, a benefit seen across prognostic risk groups and regardless of PD‑L1 expression...

Which study reported OS results...

04/15/2021

Oncology

Test Your Knowledge

Quiz: Which Combo Regimen Received FDA Approval for Treatment of Advanced RCC?

02/02/2021

Which combo therapy regimen was approved by the FDA for the treatment of advanced RCC in January 2021?

Which combo therapy regimen was...

02/02/2021

Oncology

Test Your Knowledge

Quiz: Which Therapy Had Higher Safety, OS in Papillary RCC?

10/13/2020

Which therapy had a better safety profile and OS rate in the SAVOIR trial for papillary RCC?

Which therapy had a better...

10/13/2020

Oncology

Test Your Knowledge

Quiz: Is Pembrolizumab Plus Bevacizumab Beneficial for Metastatic RCC?

09/02/2020

True or False: Pembrolizumab combined with bevacizumab was proven safe and active in a study of patients with metastatic clear cell renal cell carcinoma.

True or False: Pembrolizumab...

09/02/2020

Oncology

Test Your Knowledge

Quiz: Is Ipilimumab Plus Nivolumab Active in Patients with Metastatic RCC?

07/31/2020

True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.

True or false: Ipilimumab plus...

07/31/2020

Oncology

Test Your Knowledge

Quiz: Does Nivolumab–Ipilimumab Yield Long-Term Benefit in Advanced RCC?

10/01/2019

True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.

True or False: Combining...

10/01/2019

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology